Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;24(6):1472-8.
doi: 10.1093/annonc/mdt018. Epub 2013 Feb 14.

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel

D L Hertz  1 , S Roy, A A Motsinger-Reif, A Drobish, L S Clark, H L McLeod, L A Carey, E C Dees
Affiliations

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel

D L Hertz et al. Ann Oncol. 2013 Jun.

Abstract

Background: Paclitaxel-induced neuropathy is an adverse event that often leads to therapeutic disruption and patient discomfort. We attempted to replicate a previously reported association between increased neuropathy risk and CYP2C8*3 genotype.

Patients and methods: Demographic, treatment, and toxicity data were collected for paclitaxel-treated breast cancer patients who were genotyped for the CYP2C8*3 K399R (rs10509681) variant. A log-rank test was used in the primary analysis of European-American patients. An additional independent replication was then attempted in a cohort of African-American patients, followed by modeling of the entire patient cohort with relevant covariates.

Results: In the primary analysis of 209 European patients, there was an increased risk of paclitaxel-induced neuropathy related to CYP2C8*3 status [HR (per allele) = 1.93 (95% CI: 1.05-3.55), overall log-rank P = 0.006]. The association was replicated in direction and magnitude of effect in 107 African-American patients (P = 0.043). In the Cox model using the entire mixed-race cohort (n = 411), each CYP2C8*3 allele approximately doubled the patient's risk of grade 2+ neuropathy (P = 0.004), and non-Europeans were at higher neuropathy risk than Europeans of similar genotype (P = 0.030).

Conclusions: The increased risk of paclitaxel-induced neuropathy in patients who carry the CYP2C8*3 variant was replicated in two racially distinct patient cohorts.

Keywords: chemotherapy-induced peripheral neuropathy; cytochrome P450 2C8*3; paclitaxel; pharmacogenetics; race.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Incidence curve for grade 2+ neuropathy across genotype groups in the European-American cohort (n = 209). The highest risk was seen in the variant homozygotes and the lowest risk in the wild-type homozygotes.
Figure 2.
Figure 2.
Incidence curve for grade 2+ neuropathy across genotype groups in the African-American cohort (n = 107). Higher risk was seen in the carriers of the CYP2C8*3 variant when compared with the wild-type homozygotes (P = 0.043). There were no homozygous variant individuals in this cohort.
Figure 3.
Figure 3.
Incidence curve for grade 2+ neuropathy across genotype groups in the mixed-race cohort (n = 411) indicating an approximate doubling of grade 2+ neuropathy risk for each *3 variant a patient carries, supporting an additive genetic effect.
Figure 4.
Figure 4.
Incidence curve for grade 2+ neuropathy across racial groups in the entire mixed-race cohort (n = 411). After adjusting for CYP2C8*3 and age, non-European Americans (n = 124) were at higher risk of grade 2+ neuropathy than European Americans (n = 287) (P = 0.030).
See this image and copyright information in PMC

Comment in

References

    1. Gines J, Sabater E, Martorell C, et al. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol. 2011;13(7):485–498. - PubMed
    1. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686–3696. - PubMed
    1. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21(8):1431–1439. - PubMed
    1. Postma TJ, Vermorken JB, Liefting AJM, et al. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6(5):489–494. - PubMed
    1. Rowinsky EK, Chaudhry V, Cornblath DR, et al. Neurotoxicity of taxol. J Natl Cancer Inst Monogr. 1993;1993(15):107–115. - PubMed

Publication types

MeSH terms

LinkOut - more resources